## DAFTAR PUSTAKA


1. Boland M V, Giaconi JA, Lee RK, Lin SC, Muir KW, Sood S, et al. 2024-2025 Basic and Clinical Science Course, Section 10: Glaucoma. 2024;
2. Khurana A, Dada T, Kaushik S. Principles and Practice of Glaucoma. New Delhi; 2019. 3–6 p.
3. Mohammed TK, Ramulu PY, Saeedi OJ. Ophthalmology. 6th ed. Yanoff M, Duker JS, editors. Vol. I. Philadelphia: Elsevier; 2023. 947–952 p.
4. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014 Nov 1;121(11):2081–90.
5. Bourne RRA, Steinmetz JD, Saylan M, Mersha AM, Weldemariam AH, Wondmeneh TG, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb 1;9(2):e144–60.
6. Asia Pacific Glaucoma Society. Asia Pacific Glaucoma Guidelines. Fourth. Amsterdam: Kugler Publications; 2024. 13 p.
7. Rif'Ati L, Halim A, Lestari YD, Moeloek NF, Limburg H. Blindness and Visual Impairment Situation in Indonesia Based on Rapid Assessment of Avoidable Blindness Surveys in 15 Provinces. Ophthalmic Epidemiol. 2021;28(5):408–19.
8. Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. Situasi Glaukoma di Indonesia. Kementerian Kesehatan Republik Indonesia; 2019. 1–9 p.
9. Choplin NT. Classification of Glaucoma. In: Choplin NT, Traverso CE, editors. Atlas of glaucoma. Florida: CRC Press; 2014. p. 7–12.
10. Cueva Vargas J, Di Polo A. Neuroinflammation in glaucoma: soluble tumor necrosis factor alpha and the connection with excitotoxic damage. Neural Regen Res. 2016;11(3):424.
11. Adornetto A, Russo R, Parisi V. Neuroinflammation as a target for glaucoma therapy. Neural Regen Res. 2019 Mar 1;14(3):391–4.
12. Tezel G. Molecular regulation of neuroinflammation in glaucoma: Current knowledge and the ongoing search for new treatment targets. Prog Retin Eye Res. 2022 Mar 1;87:1–27.
13. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008 Jul 24;454(7203):428–35.
14. Quaranta L, Bruttini C, Micheletti E, Konstas AGP, Michelessi M, Oddone F, et al. Glaucoma and neuroinflammation: An overview. Surv Ophthalmol. 2021 Sep 1;66(5):693–713.
15. Križaj D, Ryskamp DA, Tian N, Tezel G, Mitchell CH, Slepak VZ, et al. From Mechanosensitivity to Inflammatory Responses: New Players in the Pathology of Glaucoma. Curr Eye Res. 2014 Feb;39(2):105–19.

16. Tezel G. TNF-α signaling in glaucomatous neurodegeneration. Prog Brain Res. 2008;173:409–21.
17. Cueva Vargas JL, Osswald IK, Unsain N, Aurousseau MR, Barker PA, Bowie D, et al. Soluble tumor necrosis factor alpha promotes retinal ganglion cell death in glaucoma via calcium-permeable ampa receptor activation. Journal of Neuroscience. 2015 Sep 2;35(35):12088–102.
18. Yang X, Luo C, Cai J, Powell DW, Yu D, Kuehn MH, et al. Neurodegenerative and inflammatory pathway components linked to TNF-α/TNFR1 signaling in the glaucomatous human retina. Invest Ophthalmol Vis Sci. 2011 Oct;52(11):8442–54.
19. Kitaoka Y, Kitaoka Y, Kwong JMK, Ross-Cisneros FN, Wang J, Rong KT, et al. TNF-α-induced optic nerve degeneration and nuclear factor-κB p65. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1448–57.
20. Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H, et al. Tumor necrosis factor-α mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. Journal of Neuroscience. 2006 Dec 6;26(49):12633–41.
21. Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas DG, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF- α), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012 Jul 3;7(7):1.
22. Jung Y, Ohn K, Shin H, Oh SE, Park CK, Park HYL. Factors Associated with Elevated Tumor Necrosis Factor-α in Aqueous Humor of Patients with Open-Angle Glaucoma. J Clin Med. 2022 Sep 1;11(17):1–10.
23. Beykin G, Norcia AM, Srinivasan VJ, Dubra A, Goldberg JL. Discovery and clinical translation of novel glaucoma biomarkers. Prog Retin Eye Res. 2021 Jan 1;80:1–20.
24. Agnifili L, Pieragostino D, Mastropasqua A, Fasanella V, Brescia L, Tosi GM, et al. Molecular biomarkers in primary open-angle glaucoma: from noninvasive to invasive. In: Progress in Brain Research. Elsevier B.V.; 2015. p. 1–32.
25. Walsh MM, Yi H, Friedman J, Cho KI, Tserentsoodol N, McKinnon S, et al. Gene and protein expression pilot profiling and biomarkers in an experimental mouse model of hypertensive glaucoma. Exp Biol Med. 2009 Aug;234(8):918–30.
26. Spurlock M, An W, Reshetnikova G, Wen R, Wang H, Braha M, et al. The Inflammasome-Dependent Dysfunction and Death of Retinal Ganglion Cells after Repetitive Intraocular Pressure Spikes. Cells. 2023 Nov 1;12(22):1.
27. Sawada H, Fukuchi T, Tanaka T, Abe H. Tumor Necrosis Factor-Concentrations in the Aqueous Humor of Patients with Glaucoma. Invest Ophthalmol Vis Sci. 2010;903–6.
28. Ghanem AA, Arafa LF, Elewa AM. Tumor Necrosis Factor-α and Interleukin-6 Levels in Patients with Primary Open-Angle Glaucoma. J Clin Exp Ophthalmol. 2011;02(01):1–6.

29. Weinreb RN. Medical Treatment: Neuroprotection. In: Giaconi JA, Law SK, Nouri-Mahdavi K, Coleman AL, Caprioli J, editors. Pearls of Glaucoma Management. Berlin: Springer; 2016. p. 259–64.
30. Ng TK, Chu KO, Wang CC, Pang CP. Green Tea Catechins as Therapeutic Antioxidants for Glaucoma Treatment. Antioxidants. 2023 Jul 1;12(7):1–23.
31. Yang H, Xue X, Li H, Apandi SN, Tay-Chan SC, Ong SP, et al. The relative antioxidant activity and steric structure of green tea catechins – A kinetic approach. Food Chem. 2018 Aug 15;257:399–405.
32. Hara Y. Tea catechins and their applications as supplements and pharmaceutics. Pharmacol Res. 2011;64(2):100–4.
33. Chu KO, Chan KP, Yang YP, Qin YJ, Li WY, Chan SO, et al. Effects of EGCG content in green tea extract on pharmacokinetics, oxidative status and expression of inflammatory and apoptotic genes in the rat ocular tissues. Journal of Nutritional Biochemistry. 2015 Nov 1;26(11):1357–67.
34. Byun EB, Kim WS, Sung NY, Byun EH. Epigallocatechin-3-Gallate Regulates Anti-Inflammatory Action Through 67-kDa Laminin Receptor-Mediated Tollip Signaling Induction in Lipopolysaccharide-Stimulated Human Intestinal Epithelial Cells. Cellular Physiology and Biochemistry. 2018 May 1;46(5):2072–81.
35. Yang Y, Xu C, Chen Y, Liang JJ, Xu Y, Chen SL, et al. Green Tea Extract Ameliorates Ischemia-Induced Retinal Ganglion Cell Degeneration in Rats. Oxid Med Cell Longev. 2019;2019:1–10.
36. Zhang WH, Chen Y, Gao LM, Cao YN. Neuroprotective role of epigallocatechin-3-gallate in acute glaucoma via the nuclear factor-κB signalling pathway. Exp Ther Med. 2021 Aug 31;22(5).
37. Shen C, Chen L, Jiang L, Lai TYY. Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma. Neurosci Lett. 2015 Jul 3;600:132–6.
38. Ren JL, Yu QX, Liang WC, Leung PY, Ng TK, Chu WK, et al. Green tea extract attenuates LPS-induced retinal inflammation in rats. Sci Rep. 2018 Dec 1;8(1):1–10.
39. Johnson Thomas V, Tomarev S. Animal models of Ophthalmic Diseases [Internet]. London: Springer; 2016. 31–43 p. Available from: http://www.springer.com/series/5332
40. Baudouin C, Kolko M, Melik Parsadaniantz S, Messmer EM, Melik-Parsadaniantz S. Inflammation in Glaucoma: From the back to the front of the eye, and beyond. Prog Retin Eye Res [Internet]. 2021;83:1–27. Available from: www.elsevier.com/locate/preteyeres
41. Brar VS, Couser NL, Singh Dhalla M, Goldman DJ, Kang KB, Richards NQ, et al. Editorial Committee BCSC ® Basic and Clinical Science Course ™ Fundamentals and Principles of Ophthalmology 2. 2024;
42. Kim SJ, Fawzi A, Kovach JL, Patel S, Recchia FM, Sobrin L, et al. Editorial Committee BCSC ® Basic and Clinical Science Course ™ Retina and Vitreous 12. 2024;

43. Ann Remington L, Goodwin D. Clinical anatomy and physiology of the visual system. Forth. Clinical anatomy and physiology of the visual system. Missouri: Elsevier; 2021. 109–120 p.
44. Levin LA, E Nilsson SF, Ver Hoeve J, Wu S, Kaufman PL, Alm A. Adler's Physiology of the Eye: Expert Consult, 11Th Edition. 2011.
45. Khurana A, Khurana I, Khurana B. Disorders of Retina and Vitreous Modern System of Ophthalmology [MSO] Series. New Delhi; 2018.
46. Aldeen S, Alryalat S. Basics of Vitreous for Ophthalmology Board Exams. In: Ophthalmology Basics for Board and FRCS Part 1 Exams Eye Yield. London: Springer; 2021. p. 85–90.
47. Forrester JV., Dick AD., McMenamin PG., Roberts Fiona, Pearlman Eric. The eye : basic sciences in practice. Elsevier; 2021. 542 p.
48. Pineles SL, Balcer LJ. Liu, Volpe, and Galetta's Neuro-Ophthalmology: Diagnosis and Management. Third. Liu GT, Volpe NJ, Galetta SL, editors. Missouri: Elsevier; 2018. 101–108 p.
49. Loewen N, Tanna A. Glaucoma Risk Factors: Intraocular Pressure. In: Schacknow PN, Samples JR, editors. The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care. Springer; 2010. p. 35–45.
50. Mathew R, Sivaprasad S. Retina. In: Riordan-Eva P, Augsburger JJ, editors. Vaughan Asbury's General Ophthalmology. 19th ed. London: McGraw-Hill Education; 2018. p. 433–5.
51. Kuriakose T. Examination of Posterior Segment. In: Clinical Insights and Examination Techniques in Ophthalmology. Springer; 2020. p. 169–74.
52. Khurana A. Glaucoma. In: Comprehensive Ophthalmology. Seventh. New Delhi: Jaypee Brothers Medical Publishers; 2019. p. 226–42.
53. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: A review. JAMA. 2014 May 14;311(18):1901–11.
54. Morgan JE, Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG. Pathogenesis of Glaucomatous Optic Neuropathy. In: Glaucoma. London: Elsevier; 2015. p. 57–93.
55. Tektas OY, Lütjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res. 2009 Apr 30;88(4):769–75.
56. Johnson M, Chan D, Read AT, Christensen C, Sit A, Ross Ethier C. The Pore Density in the Inner Wall Endothelium of Schlemm's Canal of Glaucomatous Eyes. Invest Ophthalmol Vis Sci. 2002;2950–5.
57. Quigley HA, Mckinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, Kerrigan DF, et al. Retrograde Axonal Transport of BDNF in Retinal Ganglion Cells Is Blocked by Acute IOP Elevation in Rats. Invest Ophthalmol Vis Sci. 2000;3460–6.
58. Ju WK, Kim KY, Lindsey JD, Angert M, Duong-Polk KX, Scott RT, et al. Intraocular pressure elevation induces mitochondrial fission and triggers OPA1 release in glaucomatous optic nerve. Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4903–11.

59. Resch H, Garhofer G, Fuchsjäger-Mayrl G, Hommer A, Schmetterer L. Endothelial dysfunction in glaucoma. Acta Ophthalmol. 2009 Feb;87(1):4–12.
60. Chauhan BC. Ocular Blood Flow. New York: Springer; 2012. 411–422 p.
61. Crish SD, Calkins DJ. Neurodegeneration in glaucoma: Progression and calcium-dependent intracellular mechanisms. Neuroscience. 2011 Mar 10;176:1–11.
62. Zheng Y, Wong TY, Mitchell P, Friedman DS, He M, Aung T. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: The singapore malay eye study. Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3399–404.
63. Kuang TM, Xirasagar S, Kao YW, Shia BC, Lin HC. Association of Systemic Hypertension With Primary Open-angle Glaucoma: A Population-based Case-Control Study. Am J Ophthalmol. 2020 Oct 1;218:99–104.
64. Ramakhrisnan R, Krishnadas S, Khurana M, Robin AL. Diagnosis and Management of Glaucoma. New Delhi: Jaypee Brothers Medical Publishers; 2013. 8 p.
65. Sihota R. Practical Approach to Glaucoma Case Based. New Delhi: Thieme; 2021. 91–104 p.
66. Bhartiya Shibal, Ichhpujani Parul. Manual of glaucoma. Jaypee Brothers Medical Publishers; 2016. 514 p.
67. Zhao T, Li C, Wang S, Song X. Green Tea (Camellia sinensis): A Review of Its Phytochemistry, Pharmacology, and Toxicology. Molecules. 2022 Jun 1;27(12):1–23.
68. Li J, Du L, He JN, Chu KO, Guo CL, Wong MOM, et al. Anti-inflammatory Effects of GTE in Eye Diseases. Front Nutr. 2021 Dec 13;8:1–12.
69. Yokozawa T, Dong E. Influence of green tea and its three major components upon low-density lipoprotein oxidation. Experimental and Toxicologic Pathology. 1997;49(5):329–35.
70. Hsu YW, Tsai CF, Ting HC, Chen WK, Yen CC. Green tea supplementation in mice mitigates senescence-induced changes in brain antioxidant abilities. J Funct Foods. 2014;7(1):471–8.
71. Luo KW, Ko CH, Yue GGL, Lee JKM, Li KK, Lee M, et al. Green tea (Camellia sinensis) extract inhibits both the metastasis and osteolytic components of mammary cancer 4T1 lesions in mice. Journal of Nutritional Biochemistry. 2014;25(4):395–403.
72. Cerezo-Guisado MI, Zur R, Lorenzo MJ, Risco A, Martín-Serrano MA, Alvarez-Barrientos A, et al. Implication of Akt, ERK1/2 and alternative p38MAPK signalling pathways in human colon cancer cell apoptosis induced by green tea EGCG. Food and Chemical Toxicology. 2015 Oct 1;84:125–32.
73. Ma Y, Shi Y, Li W, Sun A, Zang P, Zhang P. Epigallocatechin-3-gallate regulates the expression of Kruppel-like factor 4 through myocyte enhancer factor 2A. Cell Stress Chaperones. 2014;19(2):217–26.
74. Park JW, Hong JS, Lee KS, Kim HY, Lee JJ, Lee SR. Green tea polyphenol (-)-epigallocatechin gallate reduces matrix metalloproteinase-9 activity

following transient focal cerebral ischemia. Journal of Nutritional Biochemistry. 2010 Nov;21(11):1038–44.
75. Tai KK, Truong DD. (-)-Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, reduces dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SHSY-5Y cells. Neurosci Lett. 2010 Oct;482(3):183–7.
76. Chow HHS, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiology Biomarkers and Prevention. 2006 Dec;15(12):2473–6.
77. Isomura T, Suzuki S, Origasa H, Hosono A, Suzuki M, Sawada T, et al. Liver-related safety assessment of green tea extracts in humans: A systematic review of randomized controlled trials. Eur J Clin Nutr. 2016 Nov 1;70(11):1221–9.
78. Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food and Chemical Toxicology. 2010 Jan;48(1):409–16.
79. Chu KO, Pang CCP. Pharmacokinetics and Disposition of Green Tea Catechins. In: Pharmacokinetics and Adverse Effects of Drugs - Mechanisms and Risks Factors. InTechOpen; 2018. p. 17–36.
80. Chen ZY, Zhu QY, Tsang D, Huang Y. Degradation of green tea catechins in tea drinks. J Agric Food Chem. 2001;49(1):477–82.
81. Ojima T, Yoshimura N. Mechanisms of The Glaucomas: Disease processes and therapeutic modalities. Tombran-Tink J, Barnstable CJ, Shield MB, editors. Philadephia: Humana Press; 2008. 459–465 p.
82. Modlinska K, Pisula W. The natural history of model organisms the norway rat, from an obnoxious pest to a laboratory pet. Elife. 2020;9:1–13.
83. Pang IH, Clark AF. Inducible rodent models of glaucoma. Prog Retin Eye Res. 2020;75:1–35.
84. Morrison JC, Johnson E, Cepurna WO. Rat models for glaucoma research. Prog Brain Res. 2008;173:285–301.
85. Bai YJ, Zhu YT, Chen Q, Xu J, Sarunic M V., Saragovi UH, et al. Validation of glaucoma-like features in the rat episcleral vein cauterization model. Chin Med J (Engl). 2014;127(2):359–64.
86. Urcola JH, Hernández M, Vecino E. Three experimental glaucoma models in rats: comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp Eye Res. 2006 Aug;83(2):429-37.
87. J. Ruiz-Ederra, A.S. Verkman. Mouse model of sustained elevation in intraocular pressure produced by episcleral vein occlusion. Experimental Eye Research 82 (2006) 879–884.
88. Xu H, Gan C, Xiang Z, Xiang T, Li J, Huang X, Qin X, Liu T, Sheng J, Wang X. Targeting the TNF-α-TNFR interaction with EGCG to block NF-κB signaling in human synovial fibroblasts. Biomed Pharmacother. 2023.1-12.

89. Chidlow G, Wood JPM, Casson RJ. Investigations into Hypoxia and Oxidative Stress at the Optic Nerve Head in a Rat Model of Glaucoma. Front Neurosci. 2017 Aug 24;11:478.
90. Kondkar AA, Sultan T, Almobarak FA, Kalantan H, Al-Obeidan SA, Abu-Amero KK. Association of increased levels of plasma tumor necrosis factor alpha with primary open-angle glaucoma. Clinical Ophthalmology. 2018:12. 701-06.